Member Info for Brighty1

The best advice is always to "Follow the money". With ODX it is obvious what is going to happen here as the significant buying on 17th, 18th November and the buying today confirms that people have started dong the maths. As I keep flagging up, the revenue stream for ODX is going to be huge according to the various RNS' and the presentation the other evening. So for me it signals fab gains potentially to be made here. Testing is not going anywhere for a long long time and will work hand in glove with vaccines. That was what the RTC consortia was all about and we have "not less than" 25% of the RTC manufacturing pie. Good luck, Brighty

New CEO with a New Broom = New Momentum. We are heading to £1+ plus within 12 months, if not sooner. Good luck, Brighty

Follow the money. Lots of late reported large buys in ODX, just published . Good luck, Brighty
24-Nov-20 16:27:47 47.00 42,551 Sell* 47.00 48.00 20.00k O
24-Nov-20 16:20:29 47.50 32,000 Unknown* 47.00 48.00 15.20k O
24-Nov-20 16:14:37 48.275 41,414 Buy* 47.00 48.00 19.99k O
24-Nov-20 16:14:03 48.24 31,080 Buy* 47.00 48.00 14.99k O
24-Nov-20 16:17:42 48.02 20,000 Buy* 47.00 48.00 9,604 O
24-Nov-20 16:15:07 48.25 16,614 Buy* 47.00 48.00 8,016 O
23-Nov-20 14:17:34 53.74 46,496 Buy* 47.00 48.00 24.99k O
23-Nov-20 08:30:00 53.97 45,000 Buy* 47.00 48.00 24.29k O
23-Nov-20 08:07:20 56.94 38,775 Buy* 47.00 48.00 22.08k O
23-Nov-20 14:40:19 53.90 50,000 Buy* 47.00 48.00 26.95k O
23-Nov-20 13:20:19 53.6196 55,355 Buy* 47.00 48.00 29.68k O
23-Nov-20 09:54:41 54.60 46,769 Buy* 47.00 48.00 25.54k O
23-Nov-20 08:37:13 53.00 100,000 Buy* 47.00 48.00 53.00k O
23-Nov-20 08:20:25 55.10 40,000 Buy* 47.00 48.00 22.04k O
23-Nov-20 08:48:52 54.295 55,000 Buy* 47.00 48.00 29.86k O
23-Nov-20 12:04:00 55.30 55,000 Buy* 47.00 48.00 30.42k O
23-Nov-20 12:48:39 55.00 100,000 Buy* 47.00 48.00 55.00k O
23-Nov-20 11:24:18 56.7728 48,920 Buy* 47.00 48.00 27.77k O
24-Nov-20 16:18:29 48.0471 10,142 Sell* 48.00 49.00 4,873 O
24-Nov-20 14:17:25 48.1555 32,361 Sell* 48.00 49.00 15.58k O
24-Nov-20 14:17:05 49.99 39,982 Buy* 48.00 49.00 19.99k O
24-Nov-20 15:16:53 48.65 20,000 Buy* 48.00 49.00 9,730

Just a few of the late reported buys from yesterday published this morning. See below. Good luck, Brighty
23-Nov-20 09:39:09 99.25 25,000 Buy* 88.00 90.00 24.81k O
23-Nov-20 15:12:21 94.0105 42,556 Buy* 88.00 90.00 40.01k O
23-Nov-20 09:36:45 99.00 25,000 Buy* 88.00 90.00 24.75k O
23-Nov-20 11:24:37 96.995 25,000 Buy* 88.00 90.00 24.25k O
23-Nov-20 11:37:18 96.55 25,000 Buy* 88.00 90.00 24.14k O
23-Nov-20 15:26:45 94.30 25,000 Buy* 88.00 90.00 23.58k O
23-Nov-20 11:13:41 96.995 30,000 Buy* 88.00 90.00 29.10k O
23-Nov-20 15:52:09 91.2477 36,330 Buy* 88.00 90.00 33.15k O
23-Nov-20 15:28:09 94.00 30,200 Buy* 88.00 90.00 28.39k O
23-Nov-20 14:07:35 95.50 136,427 Buy* 88.00 90.00 130.29k O
23-Nov-20 12:04:19 96.10 40,000 Buy* 88.00 90.00 38.44k O
23-Nov-20 14:31:15 94.50 26,456 Buy* 88.00 90.00 25.00k O
23-Nov-20 14:10:34 95.00 25,000 Buy* 88.00 90.00 23.75k O
23-Nov-20 14:44:43 95.00 50,000 Buy* 88.00 90.00 47.50k O
23-Nov-20 15:08:11 94.50 25,000 Buy* 88.00 90.00 23.63k O
23-Nov-20 14:48:31 94.975 25,000 Buy* 88.00 90.00 23.74k O
23-Nov-20 14:07:42 95.50 65,000 Buy* 88.00 90.00 62.08k O
23-Nov-20 16:29:34 92.50 31,263 Buy* 88.00 90.00 28.92k O
23-Nov-20 13:57:34 95.50 35,000 Buy* 88.00 90.00 33.43k O
23-Nov-20 09:17:02 97.84 25,000 Buy* 88.00 90.00 24.46k O
23-Nov-20 14:00:23 95.00 23,295 Buy* 88.00 90.00 22.13k O
23-Nov-20 08:34:25 97.00 30,000 Buy* 88.00 90.00 29.10k O
23-Nov-20 08:53:45 98.00 50,000 Buy* 88.00 90.00 49.00k O
23-Nov-20 09:09:05 96.975 23,014 Buy* 88.00 90.00 22.32k O
23-Nov-20 13:51:21 95.50 27,500 Buy* 88.00 90.00 26.26k O
23-Nov-20 10:43:45 97.1666 25,000 Buy* 88.00 90.00 24.29k O
23-Nov-20 13:51:29 95.50 27,500 Buy* 88.00 90.00 26.26k O
23-Nov-20 13:09:21 95.949 25,000 Buy* 88.00 90.00 23.99k O
23-Nov-20 15:30:17 94.17 29,500 Buy* 88.00 90.00 27.78k O
23-Nov-20 08:31:57 98.26683 35,603 Buy* 88.00 90.00 34.99k O
23-Nov-20 16:22:36 92.6501 23,703 Buy* 88.00 90.00 21.96k O
23-Nov-20 08:00:31 102.82416 39,672 Buy* 88.00 90.00 40.79k O
23-Nov-20 10:42:20 97.75 50,000 Buy* 88.00 90.00 48.88k O
23-Nov-20 14:44:37 95.00 25,000 Buy* 88.00 90.00 23.75k O
23-Nov-20 13:57:40 95.50 35,000 Buy* 88.00 90.00 33.43k O
23-Nov-20 08:29:11 96.40 25,000 Buy* 88.00 90.00 24.10k O
23-Nov-20 16:08:55 93.00 25,000 Buy* 88.00 90.00 23.25k O
23-Nov-20 14:44:32 95.00 25,000 Buy* 88.00 90.00 23.75k O
23-Nov-20 08:39:51 96.6971 30,000 Buy* 88.00 90.00 29.01k O
23-Nov-20 14:50:31 95.00 25,000 Buy* 88.00 90.00 23.75k O
23-Nov-20 16:02:24 91.9586 40,000 Buy* 88.00 90.00 36.78k O
23-Nov-20 11:13:19 96.995 30,920 Buy* 88.00 90.00 29.99k O
23-Nov-20 10:39:19 97.75 50,000 Buy* 88.00 90.00 48.88k O
23-Nov-20 08:01:23 99.8372 22,368 Buy* 88.00 90.00 22.33k O
23-Nov-20 09:32:15 99.00 25,000 Buy* 88.00 90.00 24.75k

The late reported buys from yesterday, just published, say it all. Huge confidence in SNG. Good luck, Brighty

Great RNS today ahead of the CMD, at which our ceo will succinctly articulate why this will be above £1 within 12 months in my opinion. Good luck, Brighty

"The success against coronavirus of Synairgen’s treatment, a drug called interferon beta in a form delivered directly to the lungs, suggests that it could be effective against other respiratory diseases that we cannot expect to disappear in the next year or so. This at least is the view of one fund manager Questor spoke to and also of analysts at Numis, the broker. Now stockbrokers’ analysts can get carried away so perhaps we should take Numis’s share price target of 990p – more than 11 times the current price – with a pinch of salt. But the stock, which is quoted on Aim, may be worth a flutter with a small slice of your Isa or pension.’ Good luck, Brighty

Exactly and don't forget that SNG has demonstrated that it can save lives & boosts lung defences. So it will stop Coronavirus and Influenza attacking and damaging the lungs. That means in the pharma sector a takeover or licencing deal is a real possibility. I'm with Numis and The Lancet on how effective Synairgen is going to be in the near future. £8-10 is my prediction. Lots of news incoming. Good luck, Brighty

Bearing in mind that Abingdon stated recently that "through Oxford University’s involvement in UK-RTC, the research teams at Abingdon Health that developed the AbC-19 Rapid Test have had access to the same antigens used for developing the vaccine candidate ChAdOx1", ODX is clearly going to benefit via the RTC. "No less than 25%"as we know. Once the hype is out of the way re the AZ vaccine and people focus on the testing again that is going to be required ODX's share price will climb significantly in my opinion. Good luck, Brighty.

Yes, 33p now. It's been a long time coming. Here's to £1 in the next 6 months. Good luck everyone. Brighty

Good news from both RNS' today. A new CEO to take us forward now that Drew Nelson has taken the business back into growth and profitability with full year revenue growth of over 20%, with a mid-single-digit £m operating profit for FY20. Well done to Dr Nelson and the IQE team. All in all, whilst it has taken longer to achieve, IQE is now heading back to growth and profitability. That should see our share price hit a new 2020 high in the next 6 months. Plus don't forget that we were over 90p in 2019, over 140p in 2018 and over 170p in 2017. We should be back to those kind of prices in due course.
Key messages from today include:
* The Group anticipates that underlying demand for the technologies that IQE’s products enable will remain strong heading into 2021.
* The Group expects demand for 5G-related products, both handset and infrastructure, will continue to grow over the next few years as the mega-replacement cycle of 5G deployments gathers pace around the world.
* IQE has a leading portfolio of Photonics products, for 3D Sensing and other applications, which makes the Group well-positioned for growth.
Good luck, Brighty.

AO's results today are more good news for BWNG

AO Founder and Chief Executive, John Roberts, said: "This has been a half year like no other. I believe our market has changed as a result, forever. Online is now the dominant retail channel for customersFinancial performance".

He said it! "Online is now the dominant retail channel" Little wonder that Lord Alliance and family see huge gains to be made with BWNG with the OO and move to AIM, with AO highlighting strong revenue growth for the period increasing 53.2% to £717.0m (2019: £468.0m).

Good luck, Brighty

I agree and would suggest that it’s best to Ignore the distractions and stick to the specifics, which according to The Lancet and other respected experts is that Synairgen has established that patients who had SNG001 were more than twice as likely to recover & there were no deaths in the group taking the SNG drug formulation. i.e. they have irrefutably proved that Inhaled interferon does save lives. We also know that the data shows that SNG boosts lung defences. So SNG is the perfect treatment for Coronavirus and influenza etc. Once the vaccine hype dwindles and people focus on what SNG is all about the share price will rise substantially. Arise, Sir Stephen Holgate. Good luck, Brighty

Yes, the Merck deal appears to be about reducing the risk of respiratory failure. This is good news as the next focus is clearly going to be on preventing damage to lungs / respiratory function once the vaccine news dwindles. This is SNG's area of expertise. A takeover or licencing deal from one of the majors just got a bit closer. Good luck, Brighty

Breaking news just now re Merck. Interesting indeed.... Good luck, Brighty
MSD has agreed to acquire drugmaker OncoImmune in a deal that will give it control of a drug that could help ease symptoms and reduce deaths in patients with severe or critical cases of COVID-19.

Merck is paying $425 million for the private company, in addition to extra payments for regulatory milestones and sales. Merck has built out its portfolio of COVID-19 medicines through a series of deals in recent months, including the acquisition of Australian drugmaker Themis and a partnership with Ridgeback Biotherapeutics LP.

OncoImmune recently announced positive interim data from a phase 3 trial of its leading therapeutic candidate, CD24F, for patients with severe and critical COVID-19.

The data show that the therapy, which is administered as an injection, increased the likelihood of symptom improvement in serious COVID-19 cases and also reduced the risk of respiratory failure and death, said Roger Perlmutter, who heads research at Merck.

Yes, how true. So many well intentioned people here spreading the word about Sareum for free. An article about the company in the FT, Sunday Times, Wall Street Journal or on CNN / Sky / BBC News would also be helpful though please, Citigate / Tim. Good luck, Brighty

Well said Ahfam. I'm expecting licencing updates soon and well said Basil regarding PR / Comms. Most of us would appear to agree regarding Sareum's PR!
Good luck, Brighty

Up 40% so far to over 2p. Good to see this rise so much today but as we all know Webis is a multi bag investment opportunity just waiting to happen. Re the takeover chatter on this forum and on the back of the William Hill M&A activity a reminder that this is what Webis said recently in an RNS:

"As a result, the company has had no shortage of informal offers from other interested parties in the space, specifically in the areas of software deals, strategic alliances and, at the operating company level only, mergers and even acquisition"….

Hence why I am a long term shareholder in Webis. Here's to a great outcome whether it is M&A or sports betting in California. which will see this multi bag significantly. Brighty

And Dr Owen is also Chairman of Avacta’s scientific advisory board. AVCT, as we all know, have had an incredible year. Hopefully Dr Owen can replicate this success at Sareum. Good luck all Sareum investors, Brighty

What’s becoming increasingly more and more intriguing here is that N4P’s rolling SARS-CoV-2 spike testing experiment to see whether Nuvec® loaded with pDNA can produce an antibody reaction in mice is going to be of interest to a licencing partner or even an M&A suitor. Furthermore, the promising provisional data from the Moderna & Pfizer P3 mRNA-based vaccine candidates really do underscore the efficacy of DNA/RNA vaccines. The pharma sector will now know following N4P’s RNS a couple of weeks ago that Nuvec loaded with pDNA, can be dried, kept at room temperature and put back together without any degradation of the pDNA. Therefore Nigel Theobald’s ‘collaboration’ talks will have been strengthened in the last couple of weeks as we now know that the Pfizer COVID vaccine has to be stored at -70°C. All in all things are really starting to look very interesting indeed. Good luck all “N4Pers”, Brighty